EU committee recommends cutting time for generic pricing decisions

The European Parliament's Environment and Public Health Committee approved on Tuesday amendments to a proposed Transparency Directive that would require member states to make pricing and reimbursement decisions on generic medicines within 60 days of approval. Member states will still have 180 days to issue a decision for innovative drugs. In a draft of the directive that was published in March, the European Commission had proposed to reduce the timeline for pricing and reimbursement decisions to within 30 days of approval of a generic and within 120 days of approval of an innovative drug (see BioCentury Extra, March 1). ...